GHRH (1–44) vs MK-677
Both GHRH (1–44) and MK-677 are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
GHRH (1–44)
Evidence AGrowth Hormone Releasing Hormone, full sequence
The full 44-amino-acid GHRH sequence. The natural pituitary stimulus for GH release. Largely supplanted in clinical use by sermorelin/tesamorelin but remains a research and diagnostic tool.
View full GHRH (1–44) profile →MK-677
Evidence B+Ibutamoren (MK-677)
An orally active ghrelin-receptor agonist that drives 24-hour increases in GH and IGF-1. Technically a non-peptide small molecule but always grouped with GH peptides.
View full MK-677 profile →Side-by-Side
| Attribute | GHRH (1–44) | MK-677 |
|---|---|---|
| Evidence Grade | A | B+ |
| FDA Status | FDA-approved (Geref) historically as diagnostic GH stimulant; current US availability limited | Not FDA-approved — investigational (orally active GH secretagogue) |
| Typical Dose | 1 mcg/kg IV (diagnostic test) | 10–25 mg orally, once daily |
| Clinics Indexed | 22 | 165 |
| Categories | growth-hormone | growth-hormone, anti-aging |
Key reported benefits — GHRH (1–44)
- ✓Endogenous GH stimulation
- ✓Diagnostic GH testing
Key reported benefits — MK-677
- ✓Sustained GH/IGF-1 elevation
- ✓Sleep depth
- ✓Lean mass
- ✓Bone density
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.